Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01072773 · OUTCOME

Overall Survival

Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis · Source last updated 2014-04-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Duration of Study (up to 5 years)

What was measured

Survival time is defined as the time from registration to death due to any cause.

Groups in this outcome

Bortez/Cyc/Dex

Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bortez/Cyc/Dex2

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Bortez/Cyc/Dex1.45Not reported1.351.54Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.35
        upper Limit
        1.54
        value
        1.45
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    units
    Participants
description
Survival time is defined as the time from registration to death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.
    id
    OG000
    title
    Bortez/Cyc/Dex
param Type
MEDIAN
reporting Status
POSTED
time Frame
Duration of Study (up to 5 years)
title
Overall Survival
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice